期刊
PHARMACEUTICS
卷 14, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14071495
关键词
mesoporous silica nanoparticles; CRISPR-Cas9; gene editing; inflammation; drug delivery
资金
- MCIN/AEI [RTI2018-100910-B-C41]
- FEDER A way to make Europe
- Generalitat Valenciana [PROMETEO 2018/024]
- Spanish Government
This article reports the development of nanoparticles capable of delivering CRISPR-Cas9 gene-editing machinery and releasing drugs for one-shot treatments. The nanoparticles show promise in treating inflammatory diseases by simultaneously editing the key protein involved in inflammatory cell death and delivering an anti-inflammatory drug. The study demonstrates the potential of these nanoparticles as a versatile platform for gene-editing and drug therapy.
In this article, we report one of the few examples of nanoparticles capable of simultaneously delivering CRISPR-Cas9 gene-editing machinery and releasing drugs for one-shot treatments. Considering the complexity of inflammation in diseases, the synergistic effect of nanoparticles for gene-editing/drug therapy is evaluated in an in vitro inflammatory model as proof of concept. Mesoporous silica nanoparticles (MSNs), able to deliver the CRISPR/Cas9 machinery to edit gasdermin D (GSDMD), a key protein involved in inflammatory cell death, and the anti-inflammatory drug VX-765 ((CRISPR)-C-GSDMD45-VX-MSNs), were prepared. Nanoparticles allow high cargo loading and CRISPR-Cas9 plasmid protection and, thus, achieve the controlled codelivery of CRISPR-Cas9 and the drug in cells. Nanoparticles exhibit GSDMD gene editing by downregulating inflammatory cell death and achieving a combined effect on decreasing the inflammatory response by the codelivery of VX-765. Taken together, our results show the potential of MSNs as a versatile platform by allowing multiple combinations for gene editing and drug therapy to prepare advanced nanodevices to meet possible biomedical needs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据